Table 1.
Total No. of Cases (n = 11 308) | No. (%) |
---|---|
Estimated gestational age (n = 2824)a | |
1st trimester (1–12 wk) | 66 (2) |
2nd trimester (13–27 wk) | 574 (20) |
3rd trimester (>28 wk) | 2184 (77) |
Symptoms (n = 11 308) | |
Cough | 2704 (24) |
Fever | 2051 (18) |
Fatigue, malaise, myalgias | 1525 (13) |
Headache | 1448 (13) |
Shortness of breath, dyspnea | 1391 (12) |
Otherb | 4120 (36) |
Asymptomatic | 366 (3) |
Severity (as defined by authors; n = 1999) | |
Mild–moderatec | 1583 (79) |
Severe/ICU | 416 (21) |
Investigational treatment reported (n = 184)d | |
Hydroxychloroquine | 106 (58) |
Lopinavir/ritonavir | 39 (21) |
Remdesivir | 13 (7) |
IL-1, IL-6 inhibitors | 13 (7) |
IVIG or gamma globulin | 9 (5) |
Convalescent plasma | 4 (2) |
Maternal outcomes (n = 10 597) | |
Alive to delivery | 10 437 (98) |
Died | 33 (0.3) |
Still hospitalized | 127 (1.0) |
Pregnancy outcomes (n = 2297) | |
Live births | 1375 (60) |
In utero, pregnancy ongoing | 869 (38) |
Spontaneous miscarriage (<20 wk) | 20 (0.9) |
Elective abortion | 17 (0.7) |
Stillbirth (>20 wk) | 14 (0.6) |
Ectopic pregnancy | 2 (0.08) |
Gestational age at birth (n = 868) | |
Term | 695 (80) |
Preterm (<37 wk) | 173 (20) |
Delivery type (n = 871) | |
Vaginal delivery | 259 (30) |
Cesarean section | 612 (70) |
Neonatal outcomes (n = 1163) | |
Alive | 1155 (99) |
Neonatal death | 8 (0.7) |
Abbreviations: ICU, intensive care unit; IL, interleukin; IVIG, intravenous immunoglobulin.
aOne large cohort study (n = 8207) did not have estimated gestational ages available.
bOther symptoms included diarrhea (n = 596), nausea/vomiting (n = 700), sore throat (n = 1005), loss of taste or smell (n = 803), and chills (n = 1016).
cIncluded asymptomatic cases.
dTreatment received at any time during pregnancy or postpartum after the time of COVID-19 diagnosis. Some women may have received multiple treatments.